WESTPORT, Jun 24 (Reuters) - FDA officials yesterday approved
expanded indications for docetaxel (Taxotere) for
Injection Concentrate. The drug, manufactured by Rhone Poulenc Rorer,
can now be prescribed as first-line treatment for metastatic breast
cancer in patients refractory to adjuvant therapy. Docetaxel was
previously approved by the FDA for treatment of patients refractory to
anthracycline-based therapy.
HOpe this information benefits.
God Bless
marty auslander
------------------------------------------------------------------------
This is an automatically-generated notice. If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------
